These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30174587)

  • 1. Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration.
    Rao SS; Adlard PA
    Front Mol Neurosci; 2018; 11():276. PubMed ID: 30174587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology.
    Rao SS; Lago L; Volitakis I; Shukla JJ; McColl G; Finkelstein DI; Adlard PA
    Neurotherapeutics; 2021 Apr; 18(2):1081-1094. PubMed ID: 33410108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau
    Miao J; Shi R; Li L; Chen F; Zhou Y; Tung YC; Hu W; Gong CX; Iqbal K; Liu F
    Front Aging Neurosci; 2019; 11():34. PubMed ID: 30890929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy.
    Rao SS; Portbury SD; Lago L; Bush AI; Adlard PA
    J Alzheimers Dis; 2020; 77(2):753-771. PubMed ID: 32741833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of NFT: Biochemical Approach.
    Hasegawa M
    Adv Exp Med Biol; 2019; 1184():23-34. PubMed ID: 32096025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.
    An WL; Cowburn RF; Li L; Braak H; Alafuzoff I; Iqbal K; Iqbal IG; Winblad B; Pei JJ
    Am J Pathol; 2003 Aug; 163(2):591-607. PubMed ID: 12875979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
    Iqbal K; Gong CX; Liu F
    Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pinning down phosphorylated tau and tauopathies.
    Lim J; Lu KP
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):311-22. PubMed ID: 15615648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.
    Imahori K; Uchida T
    J Biochem; 1997 Feb; 121(2):179-88. PubMed ID: 9089387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease.
    Yamamoto A; Shin RW; Hasegawa K; Naiki H; Sato H; Yoshimasu F; Kitamoto T
    J Neurochem; 2002 Sep; 82(5):1137-47. PubMed ID: 12358761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART.
    Kaufman SK; Del Tredici K; Thomas TL; Braak H; Diamond MI
    Acta Neuropathol; 2018 Jul; 136(1):57-67. PubMed ID: 29752551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Dental Pulp Stem Cells Display a Potential for Modeling Alzheimer Disease-Related Tau Modifications.
    Gazarian K; Ramirez-Garcia L; Tapía Orozco L; Luna-Muñoz J; Pacheco-Herrero M
    Front Neurol; 2020; 11():612657. PubMed ID: 33569035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperphosphorylation determines both the spread and the morphology of tau pathology.
    Hu W; Zhang X; Tung YC; Xie S; Liu F; Iqbal K
    Alzheimers Dement; 2016 Oct; 12(10):1066-1077. PubMed ID: 27133892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.